Cellectis SA (CLLS) has released an update.
Cellectis SA, a leader in gene-editing technology for cell and gene therapies, is set to release its third quarter 2024 financial results on November 4, following the market close. Investors can expect an update on business activities during a conference call on November 5. Cellectis continues to innovate in the field of CAR-T immunotherapies and gene editing solutions.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
